April 29 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:
ENTERS LICENSE AGREEMENT WITH SANDOZ FOR HLX13
SANDOZ GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE HLX13 IN MULTIPLE REGIONS
SANDOZ TO PAY HENLIUS $31 MILLION UPFRONT
TO RECEIVE UP TO $270 MILLION IN MILESTONE PAYMENTS
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.